1
|
Thorsen SU, Pipper CB, Eising S, Skogstrand K, Hougaard DM, Svensson J, Pociot F. Neonatal levels of adiponectin, interleukin-10 and interleukin-12 are associated with the risk of developing type 1 diabetes in childhood and adolescence: A nationwide Danish case-control study. Clin Immunol 2016; 174:18-23. [PMID: 27871914 DOI: 10.1016/j.clim.2016.11.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 11/11/2016] [Accepted: 11/13/2016] [Indexed: 12/15/2022]
Abstract
BACKGROUND/AIM An in-depth understanding of the early phase of type 1 diabetes (T1D) pathogenesis is important for targeting primary prevention. We examined if 14 preselected mediators of immune responses differed in neonates that later developed T1D compared to control neonates. METHODS The study is a case-control study with a 1:2 matching. The individuals were born between 1981 through 2002. Cases were validated using the National Patient Register and the Danish Childhood Diabetes Register. Interleukin(IL)-1β, IL-4, IL-6, IL-8, IL-10, IL-12p70, interferon gamma, tumor necrosis factor alpha, transforming growth factor beta 1 (active form), leptin, adiponectin, c-reactive protein, mannose-binding lectin and soluble triggering receptor expressed on myeloid cells-1 were measured by using a flowmetric Luminex xMAP® technology. We tested two models both including a number of possible confounders. In the first model (model 1) we also adjusted for HLA-DQB1 genotype. A total of 1930 groups of assay-matched cases and controls (4746 individuals) were included in the statistical analyses. RESULTS Adiponectin was negatively associated with later risk of T1D in both models (relative change (RC), model 1: 0.95, P=0.046 and model 2: 0.95, P=0.006). IL-10 and IL-12 were both positively associated with T1D risk in the model 2 (RC, 1.19, P=0.006 and 1.07, P=0.02, respectively)-these results were borderline significant in model 1, but showed the same direction as the results from model 2. CONCLUSIONS Our results indicate that specific immunological signatures are already present at time of birth in children developing T1D before the age of 18years.
Collapse
Affiliation(s)
- Steffen U Thorsen
- Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Paediatrics, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev. Denmark.
| | - Christian B Pipper
- Department of Public Health, Section of Biostatistics, University of Copenhagen, Oester Farimagsgade 5, 1710 Copenhagen K, Denmark
| | - Stefanie Eising
- Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Paediatrics, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev. Denmark
| | - Kristin Skogstrand
- Department of Congenital Disorders, Center for Neonatal Screening, Statens Serum Institut Artillerivej 5, 2300 Copenhagen S, Denmark
| | - David M Hougaard
- Department of Congenital Disorders, Center for Neonatal Screening, Statens Serum Institut Artillerivej 5, 2300 Copenhagen S, Denmark
| | - Jannet Svensson
- Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Paediatrics, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev. Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
| | - Flemming Pociot
- Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Paediatrics, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev. Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
| |
Collapse
|
2
|
Sysi-Aho M, Ermolov A, Gopalacharyulu PV, Tripathi A, Seppänen-Laakso T, Maukonen J, Mattila I, Ruohonen ST, Vähätalo L, Yetukuri L, Härkönen T, Lindfors E, Nikkilä J, Ilonen J, Simell O, Saarela M, Knip M, Kaski S, Savontaus E, Orešič M. Metabolic regulation in progression to autoimmune diabetes. PLoS Comput Biol 2011; 7:e1002257. [PMID: 22046124 PMCID: PMC3203065 DOI: 10.1371/journal.pcbi.1002257] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2011] [Accepted: 09/17/2011] [Indexed: 12/31/2022] Open
Abstract
Recent evidence from serum metabolomics indicates that specific metabolic disturbances precede β-cell autoimmunity in humans and can be used to identify those children who subsequently progress to type 1 diabetes. The mechanisms behind these disturbances are unknown. Here we show the specificity of the pre-autoimmune metabolic changes, as indicated by their conservation in a murine model of type 1 diabetes. We performed a study in non-obese prediabetic (NOD) mice which recapitulated the design of the human study and derived the metabolic states from longitudinal lipidomics data. We show that female NOD mice who later progress to autoimmune diabetes exhibit the same lipidomic pattern as prediabetic children. These metabolic changes are accompanied by enhanced glucose-stimulated insulin secretion, normoglycemia, upregulation of insulinotropic amino acids in islets, elevated plasma leptin and adiponectin, and diminished gut microbial diversity of the Clostridium leptum group. Together, the findings indicate that autoimmune diabetes is preceded by a state of increased metabolic demands on the islets resulting in elevated insulin secretion and suggest alternative metabolic related pathways as therapeutic targets to prevent diabetes.
Collapse
Affiliation(s)
- Marko Sysi-Aho
- VTT Technical Research Centre of Finland, Espoo, Finland
| | - Andrey Ermolov
- Aalto University School of Science, Department of Information and Computer Science, Helsinki Institute for Information Technology HIIT, Espoo, Finland
| | | | - Abhishek Tripathi
- Helsinki Institute for Information Technology HIIT, Department of Computer Science, University of Helsinki, Finland
| | | | | | - Ismo Mattila
- VTT Technical Research Centre of Finland, Espoo, Finland
| | - Suvi T. Ruohonen
- Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
| | - Laura Vähätalo
- Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
| | | | - Taina Härkönen
- Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
| | - Erno Lindfors
- VTT Technical Research Centre of Finland, Espoo, Finland
| | | | - Jorma Ilonen
- Department of Clinical Microbiology, University of Eastern Finland, Kuopio, Finland
- Immunogenetics Laboratory, University of Turku, Turku, Finland
| | - Olli Simell
- Department of Pediatrics, University of Turku, Turku, Finland
| | - Maria Saarela
- VTT Technical Research Centre of Finland, Espoo, Finland
| | - Mikael Knip
- Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
- Department of Pediatrics, Tampere University Hospital, Tampere, Finland
- Folkhälsan Research Center, Helsinki, Finland
| | - Samuel Kaski
- Aalto University School of Science, Department of Information and Computer Science, Helsinki Institute for Information Technology HIIT, Espoo, Finland
- Helsinki Institute for Information Technology HIIT, Department of Computer Science, University of Helsinki, Finland
| | - Eriika Savontaus
- Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
- Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland
| | - Matej Orešič
- VTT Technical Research Centre of Finland, Espoo, Finland
- Institute of Molecular Medicine Finland FIMM, Helsinki, Finland
| |
Collapse
|
3
|
Xiang Y, Zhou P, Li X, Huang G, Liu Z, Xu A, Leslie RD, Zhou Z. Heterogeneity of altered cytokine levels across the clinical spectrum of diabetes in China. Diabetes Care 2011; 34:1639-41. [PMID: 21617097 PMCID: PMC3120206 DOI: 10.2337/dc11-0039] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To determine the relationship between selected cytokines and diabetes in Chinese subjects. RESEARCH DESIGN AND METHODS Adult patients with recent-onset type 1 diabetes (n=53), latent autoimmune diabetes in adults (LADA) (n=250), and type 2 diabetes (n=285) from multiple centers were compared with normal subjects (n=196). We centrally tested serum GAD antibodies (GADAs), interleukin-6 (IL-6), lipocalin 2 (LCN2), high-sensitivity C-reactive protein (hs-CRP), and adiponectin. RESULTS After adjustment for age, sex, and BMI, all diabetes types had increased IL-6 and LCN2 (P<0.01), and all four cytokines were increased in LADA (P<0.01). In type 1 diabetes, adiponectin but not hs-CRP was increased (P<0.01), whereas in type 2 diabetes, hs-CRP but not adiponectin was increased (P<0.01). Adiponectin was correlated positively with GADA titer and negatively with hs-CRP (P<0.01 for both). CONCLUSIONS In China, inflammatory markers are increased in all three major types of diabetes, but probably for different reasons, even in autoimmune diabetes.
Collapse
Affiliation(s)
- Yufei Xiang
- Institute of Metabolism and Endocrinology, The Second Xiangya Hospital and the Diabetes Center, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, China
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Féry F, Van de Velde U, Vermeulen I, De Pauw P, Mathieu C, Pipeleers DG, Gorus FK. Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia 2010; 53:36-44. [PMID: 19898832 DOI: 10.1007/s00125-009-1569-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2009] [Accepted: 09/10/2009] [Indexed: 11/29/2022]
Abstract
AIMS/HYPOTHESIS The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+) FDRs) of type 1 diabetic patients. METHODS Hyperglycaemic clamps were performed in 17 non-diabetic IA-2A(+) FDRs aged 14 to 33 years and in 21 matched healthy volunteers (HVs). Insulin and C-peptide responses were measured during the first (5-10 min) and second (120-150 min) release phase, and after glucagon injection (150-160 min). Clamp-induced C-peptide release was compared with C-peptide release during OGTT. RESULTS Seven (41%) FDRs developed diabetes 3-63 months after their initial clamp test. In all phases they had lower C-peptide responses than non-progressors (p < 0.05) and HVs (p < 0.002). All five FDRs with low first-phase release also had low second-phase release and developed diabetes 3-21 months later. Two of seven FDRs with normal first-phase but low second-phase release developed diabetes after 34 and 63 months, respectively. None of the five FDRs with normal C-peptide responses in all test phases has developed diabetes so far (follow-up 56 to 99 months). OGTT-induced C-peptide release also tended to be lower in progressors than in non-progressors or HVs, but there was less overlap in results between progressors and the other groups using the clamp. CONCLUSIONS/INTERPRETATION Clamp-derived functional variables stratify risk of diabetes in IA-2A(+) FDRs and may more consistently identify progressors than OGTT-derived variables. A low first-phase C-peptide response specifically predicts impending diabetes while a low second-phase response may reflect an earlier disease stage. TRIAL REGISTRATION ClinicalTrials.gov NCT00654121 FUNDING The insulin trial was financially supported by Novo Nordisk Pharma nv.
Collapse
Affiliation(s)
- E Vandemeulebroucke
- Diabetes Research Center, Brussels Free University-VUB, 1090 Brussels, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Chang LC, Huang KC, Wu YW, Kao HL, Chen CL, Lai LP, Hwang JJ, Yang WS. The Clinical Implications of Blood Adiponectin in Cardiometabolic Disorders. J Formos Med Assoc 2009; 108:353-66. [DOI: 10.1016/s0929-6646(09)60079-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
|
6
|
Pang TT, Narendran P. The Distribution of Adiponectin Receptors on Human Peripheral Blood Mononuclear Cells. Ann N Y Acad Sci 2008; 1150:143-5. [DOI: 10.1196/annals.1447.021] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|